Professor of Radiation Oncology, University Pennsylvania
Oncology
Dr. Stephen M. Hahn, MD
|
|
Give Review
Stephen Hahn is an expert in the field of Oncology. He researched medicine at Temple University School of Medicine. He received 4 awards: "America's Top Doctors", "Philadelphia Magazine", "America's Top Doctors for Cancer" and "CMS Meaningful Use Stage 1 Certification". Stephen Hahn is a published MD. He published 100 publications, including: 'The implementation and assessment of a quality and safety culture education program in a large radiation oncology department.'
Publications
- Increasing the Therapeutic Ratio of Stereotactic Ablative Radiotherapy by Individualized Isotoxic Dose Prescription.
- The implementation and assessment of a quality and safety culture education program in a large radiation oncology department.
- Factors associated with event reporting in the pediatric radiation oncology population using an electronic incident reporting System.
- Proton pencil beam scanning for mediastinal Lymphoma: the impact of interplay between target motion and beam scanning.
- Proton therapy for head and neck Cancer.
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in Cancer.
- Awakening the immune System with radiation: Optimal dose and fractionation.
- Galectin-1 and Immune Suppression during Radiotherapy.
- A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate Cancer.
- Academic Radiation Oncology Faculty Recruitment: A Chair's Perspective.
- Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non-small cell lung Cancer patients undergoing definitive radiation therapy: Pilot study resu...
- Principles and Reality of Proton Therapy Treatment Allocation.
- Reference pricing with evidence development: a way forward for proton therapy.
- Application of a telomerase-based circulating tumor cell (CTC) assay in bladder Cancer patients receiving postoperative radiation therapy: A case study.
- Detection of Brain tumor cells in the peripheral blood by a telomerase promoter-based assay.
- Theranostic gold nanoparticles modified for durable Systemic circulation effectively and safely enhance the radiation therapy of human sarcoma cells and tumors.
- Burnout in United States Academic Chairs of Radiation Oncology Programs.
- A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme.
- Current Status and Recommendations for the Future of Research, Teaching, and Testing in the Biological Sciences of Radiation Oncology: Report of the American Society f...
- What's in a Label? Radioimmunotherapy for Metastatic Prostate Cancer.
- Stereotactic body radiation therapy for lung Cancer.
- Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung Cancer.
- Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate Cancer.
- The Body of Evidence for Advanced Technology in Radiation Oncology.
- Hypoxia imaging markers and applications for radiation treatment planning.
- Radiation Dosimetry and Biodistribution of the Hypoxia Tracer (18)F-EF5 in Oncologic Patients.
- SU-E-T-437: Interfractional Dosimetric Verification of Lung Patients Treated by Passive Double Scattering Proton Radiotherapy.
- Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy fo...
- Radical pleurectomy and intraoperative photodynamic therapy for Malignant pleural mesothelioma.
- A Phase I Trial of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer: A Report of Tox...
- Adjuvant Radiotherapy in the Treatment of Invasive Intraductal Papillary Mucinous Neoplasm of the Pancreas: an Analysis of the Surveillance, Epidemiology, and End Resu...
- Modulation of chop-dependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
- Photodynamic therapy of Cancer: an update.
- New strategies in non-small cell lung Cancer: improving outcomes in chemoradiotherapy for locally advanced disease.
- A glimpse of the future: where will new combinations of diagnostics and therapies take us?
- Short-term and long-term health risks of nuclear-power-plant accidents.
- Adjuvant radiotherapy for completely resected stage 2 thymoma.
- Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of Malignant pleural mesothelioma.
- Introduction: non-small-cell lung Cancer and pleural malignancies: the end of the era of therapeutic nihilism?
- National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009.
- The Relationship among Hypoxia, Proliferation, and Outcome in Patients with De Novo Glioblastoma: A Pilot Study.
- Hemithoracic radiotherapy after extrapleural pneumonectomy for Malignant pleural mesothelioma: a dosimetric comparison of two well-described techniques.
- NIH state-of-the-science conference statement: diagnosis and management of ductal Carcinoma in situ (DCIS).
- Combined modality therapy in the elderly population.
- Photodynamic therapy: a light in the darkness?
- General principles of radiation and chemoradiation.
- Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy.
- Imaging and analytical methods as applied to the evaluation of vasculature and hypoxia in human Brain tumors.
- Motexafin lutetium-photodynamic therapy of prostate Cancer: short- and long-term effects on prostate-specific antigen.
- Should randomized clinical trials be required for proton radiotherapy? An alternative view.
- Patterns and levels of hypoxia in head and neck squamous cell Carcinomas and their relationship to patient outcome.
- Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir.
- Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy.
- Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy.
- Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy.
- Real-time in Situ monitoring of human prostate photodynamic therapy with diffuse light.
- A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal Carcinomatosis and sarcomatosis.
- EF5 binding and clinical outcome in human soft tissue Sarcomas.
- Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate Cancer.
- Optimized interstitial PDT prostate treatment planning with the Cimmino feasibility algorithm.
- C225 and PDT combination therapy for ovarian Cancer: the play's the thing.
- Pancreatic Cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras.
- Multidrug resistance in photodynamic therapy.
- Broadband reflectance measurements of light penetration, blood oxygenation, hemoglobin concentration, and drug concentration in human intraperitoneal tissues before an...
- Optical properties of human prostate at 732 nm measured in mediated photodynamic therapy.
- Hypoxia is important in the biology and aggression of human glial Brain tumors.
- A phase I study of topical Tempol for the prevention of alopecia induced by whole Brain radiotherapy.
- A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic Cancer.
- Hypoxia and Photofrin uptake in the intraperitoneal Carcinomatosis and sarcomatosis of photodynamic therapy patients.
- Phase II trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung Cancer with pleural spread.
- Comparative measurements of hypoxia in human Brain tumors using needle electrodes and EF5 binding.
- Signaling pathways in NSCLC as a predictor of outcome and response to therapy.
- Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.
- Elevated serum cytokine levels in mesothelioma patients who have undergone pleurectomy or extraPleural pneumonectomy and adjuvant intraoperative photodynamic therapy.
- Intraperitoneal photodynamic therapy causes a capillary-leak syndrome.
- Correlation of in vivo photosensitizer fluorescence and photodynamic-therapy-induced depth of necrosis in a murine tumor model.
- A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma.
- In vivo optical properties of normal canine prostate at 732 nm using motexafin lutetium-mediated photodynamic therapy.
- A low molecular weight antioxidant decreases weight and lowers tumor incidence.
- Farnesyltransferase inhibitors as radiation sensitizers.
- A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck Cancer.
- Pathological response to preoperative chemoradiation worsens with anemia in non-small cell lung Cancer patients.
- Rates of unconventional medical therapy use in patients with prostate Cancer: standard history versus directed questions.
- In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast Cancer.
- Cervical Cancer in Botswana: Current State and Future Steps for Screening and Treatment Programs.
- Photodynamic therapy for the treatment of non-small cell lung Cancer.
- Photodynamic therapy and the evolution of a Lung-sparing surgical treatment for mesothelioma.
- Biodistribution and dosimetry of (18)F-EF5 in Cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma.
- Patterns of recurrence in patients treated with photodynamic therapy for intraperitoneal Carcinomatosis and sarcomatosis.
- Clinical target promiscuity: lessons from ras molecular trials.
- Optimization of light source parameters in the photodynamic therapy of heterogeneous prostate.
- Explicit dosimetry for photodynamic therapy: macroscopic singlet oxygen modeling.
- The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response.
- Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated...
- The RAS signal transduction pathway and its role in radiation sensitivity.
- Protection against Adriamycin cytotoxicity and inhibition of DNA topoisomerase II activity by 3,4-dihydroxybenzoic acid.
- Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy.
- Radiation sensitization by inhibition of activated Ras.
- In vivo reflectance measurement of optical properties, blood oxygenation and motexafin lutetium uptake in canine large bowels, kidneys and prostates.
Schools
Temple University School Of Medicine
University Calif
National Institute Health
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Personal Choice PPO
- Regional Pref Network EPO
- Regional Pref Network HMO
- Regional Pref Network HMO+
- Regional Pref Network POS+
- Regional Pref Network PPO
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health America PPO
- Southern Health PPO
- Coventry Health Care of Delaware PPO
- First Health (Coventry Health Care) PPO
- Geisinger Health Plan
- HealthPartners
- Community Blue PPO
- Direct Access
- Horizon Blue Cross Blue Shield HMO
- Horizon Blue Cross Blue Shield POS
- Horizon Blue Cross Blue Shield PPO
- Choice Care PPO
- Keystone Health Plan East HMO
- Medicaid
- Medicare MCR
- MultiPlan PPO
- Freedom Plan
- QualCare HMO
- QualCare PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- Oxford Liberty
- United Healthcare
Awards
- America's Top Doctors
- Philadelphia Magazine
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
Education
-
National Institutes of Health Clinical Center -
UCSF -
Temple University School of Medicine
Hospital
-
Hospital of the University of Pennsylvania -
Penn Presbyterian Medical Center -
Philadelphia Veterans Affairs Medical Center -
Pennsylvania Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. Adam D. Cohen, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tal Z. Zaks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gataree Ngarmchamnanrith, MD |
|
|
Dr. Esha Kaul, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Holly Dushkin, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Julia Kennedy, DO |
|
|
Dr. James E. Russell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kara N. Maxwell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anjana Ranganathan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer A. Shin, MD |